Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC treatment modalities. However, recurrence or tumor metastasis remains the main challenge in the management of anaplastic thyroid cancer (...
Saved in:
| Published in | Biochimica et biophysica acta. Reviews on cancer Vol. 1878; no. 4; p. 188928 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.07.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC treatment modalities. However, recurrence or tumor metastasis remains the main challenge in the management of anaplastic thyroid cancer (ATC) and radioiodine (RAI) radioactive iodine-refractory differentiated thyroid cancer (RR-DTC). Several multi-tyrosine kinase inhibitors (MKIs), or immune checkpoint inhibitors in combination with MKIs, have emerged as novel therapies for controlling the progression of DTC, medullary thyroid cancer (MTC), and ATC. Here, we discuss and summarize the molecular basis of TC, review molecularly targeted therapeutic drugs in clinical research, and explore potentially novel molecular therapeutic targets. We focused on the evaluation of current and recently emerging tyrosine kinase inhibitors approved for systemic therapy for TC, including lenvatinib, sorafenib and cabozantinib in DTC, vandetanib, cabozantinib, and RET-specific inhibitor (selpercatinib and pralsetinib) in MTC, combination dabrafenib with trametinib in ATC. In addition, we also discuss promising treatments that are in clinical trials and may be incorporated into clinical practice in the future, briefly describe the resistance mechanisms of targeted therapies, emphasizing that personalized medicine is critical to the design of second-line therapies. |
|---|---|
| AbstractList | Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC treatment modalities. However, recurrence or tumor metastasis remains the main challenge in the management of anaplastic thyroid cancer (ATC) and radioiodine (RAI) radioactive iodine-refractory differentiated thyroid cancer (RR-DTC). Several multi-tyrosine kinase inhibitors (MKIs), or immune checkpoint inhibitors in combination with MKIs, have emerged as novel therapies for controlling the progression of DTC, medullary thyroid cancer (MTC), and ATC. Here, we discuss and summarize the molecular basis of TC, review molecularly targeted therapeutic drugs in clinical research, and explore potentially novel molecular therapeutic targets. We focused on the evaluation of current and recently emerging tyrosine kinase inhibitors approved for systemic therapy for TC, including lenvatinib, sorafenib and cabozantinib in DTC, vandetanib, cabozantinib, and RET-specific inhibitor (selpercatinib and pralsetinib) in MTC, combination dabrafenib with trametinib in ATC. In addition, we also discuss promising treatments that are in clinical trials and may be incorporated into clinical practice in the future, briefly describe the resistance mechanisms of targeted therapies, emphasizing that personalized medicine is critical to the design of second-line therapies. |
| ArticleNumber | 188928 |
| Author | Feng, Qingqing Wang, Jiafeng Zhang, Lizhuo Tan, Zhuo Ge, Minghua Li, Qinglin |
| Author_xml | – sequence: 1 givenname: Lizhuo surname: Zhang fullname: Zhang, Lizhuo organization: Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China – sequence: 2 givenname: Qingqing surname: Feng fullname: Feng, Qingqing email: fengqing910524@163.com organization: Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China – sequence: 3 givenname: Jiafeng surname: Wang fullname: Wang, Jiafeng organization: Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China – sequence: 4 givenname: Zhuo surname: Tan fullname: Tan, Zhuo email: tanzhuoyue@163.com organization: Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China – sequence: 5 givenname: Qinglin surname: Li fullname: Li, Qinglin email: qinglin200886@126.com organization: The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China – sequence: 6 givenname: Minghua surname: Ge fullname: Ge, Minghua email: geminghua@hmc.edu.cn organization: Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37257629$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kEtLxDAUhYMozkN_gSBduumYR5umggsZfMGIIgruQprcGTN0mpq0wvx7M1Zdurpncc49934TtN-4BhA6IXhGMOHn61lVadXMKKZsRoQoqdhDYyKKMqU5J_tojBnO0oyUbyM0CWGNMckZ44doxAqaF5yWY_T84GrQfa18UqlgQ6Iak3TKr6CDKN7Bq3ab2CbKrXfWJLFRg79InrxbeQhDwLWt813f2M5COEIHS1UHOP6ZU_R6c_0yv0sXj7f386tFqjOcdanJRbxBUV4UXGutKC1ZHu_OKiiUyBiGDAxRRgm2FAIbITgUHGsqMrwUJbApOhv2tt599BA6ubFBQ12rBlwfJBWUcFaWBEcrG6zauxA8LGXr7Ub5rSRY7mDKtfyGKXcw5QAzpk5_CvpqA-Yv80svGi4HA8Q3Py14GbSFyMdYD7qTxtl_C74A8jOIIA |
| CitedBy_id | crossref_primary_10_5306_wjco_v14_i12_570 crossref_primary_10_3390_cimb46030152 crossref_primary_10_1002_hsr2_1859 crossref_primary_10_1007_s12020_024_03933_x crossref_primary_10_1021_acsbiomaterials_4c00345 crossref_primary_10_1021_acsomega_4c00373 crossref_primary_10_1007_s00210_024_02961_8 crossref_primary_10_1007_s00428_024_03777_w crossref_primary_10_1007_s40291_024_00702_4 crossref_primary_10_26779_2786_832X_2023_6_23 |
| Cites_doi | 10.1089/thy.2009.0417 10.7150/thno.57689 10.1677/ERC-08-0018 10.1677/erc.1.01143 10.1002/ijc.32041 10.1016/j.isci.2019.09.030 10.1016/j.canlet.2020.08.021 10.1016/S2213-8587(13)70215-8 10.1200/JCO.20.03093 10.1002/cncr.23869 10.1158/2159-8290.CD-18-0338 10.1210/jc.2018-01478 10.1089/thy.2005.15.531 10.1089/thy.2015.0020 10.1530/ERC-22-0293 10.1080/14740338.2018.1535592 10.1038/s41574-020-00448-z 10.1001/jamaoncol.2021.6268 10.3389/fendo.2021.667784 10.1530/ERC-15-0070 10.1210/jc.2013-1450 10.1089/thy.2020.0322 10.1089/thy.2013.0594 10.1016/j.ejca.2015.05.020 10.1016/j.pharmthera.2023.108344 10.3389/fonc.2017.00025 10.1046/j.1365-2265.1999.00704.x 10.1089/thy.2021.0565 10.1158/1078-0432.CCR-20-2278 10.1210/jc.2002-021690 10.3389/fendo.2019.00421 10.1016/j.ctrv.2022.102372 10.1177/17588359221101691 10.3322/caac.21654 10.1001/jamaoncol.2020.3362 10.1089/thy.2018.0458 10.1089/thy.2019.0453 10.1158/0008-5472.CAN-09-0727 10.1200/JCO.2017.73.0226 10.3310/hta24020 10.1038/s41467-022-28848-x 10.1016/S0344-0338(00)80015-1 10.1089/thy.2020.0235 10.1089/thy.2018.0048 10.1038/nrc3431 10.1158/1078-0432.CCR-20-2950 10.1038/onc.2015.253 10.1089/thy.2012.0103 10.1210/jc.2015-4227 10.1016/j.ejca.2022.06.044 10.1210/er.2019-00007 10.3389/fendo.2022.864253 10.1016/S2213-8587(21)00120-0 10.1016/j.path.2019.08.002 10.1186/s12943-018-0903-0 10.1158/1078-0432.CCR-21-0761 10.1016/j.cell.2014.09.050 10.1200/JCO.2017.73.6785 10.1093/annonc/mdz400 10.1093/annonc/mdy137 10.1158/1078-0432.CCR-15-2298 10.1089/thy.2019.0792 10.1530/EJE-22-0312 10.3389/fendo.2022.909333 10.3310/hta23080 10.1210/clinem/dgab196 10.1677/erc.1.0978 10.3390/ijms20163934 10.1186/s12885-019-5380-3 10.1056/NEJMoa2005651 10.1016/j.semcancer.2020.11.013 10.1038/s41574-021-00484-3 10.1073/pnas.1605841113 10.3389/fimmu.2022.1055412 10.1016/j.annonc.2022.04.009 10.2147/CMAR.S340967 10.1186/s12943-018-0801-5 10.1038/nrendo.2011.142 10.1158/1078-0432.CCR-10-1627 10.1200/JCO.2011.35.5040 10.1200/JCO.2012.48.4659 10.3390/cancers13194827 10.1016/S0140-6736(14)60421-9 10.1200/JCO.19.02790 10.1530/EJE-21-1259 10.1038/s41416-018-0296-2 10.1016/j.ejca.2021.07.029 10.2217/fon-2018-0557 10.1016/j.surg.2022.05.005 10.1210/jc.2008-0273 10.1038/367375a0 10.1158/1078-0432.CCR-22-0873 10.1146/annurev-med-061512-105739 10.1016/S1470-2045(21)00332-6 10.1152/physrev.00041.2015 10.1158/1078-0432.CCR-14-2915 10.1016/S1470-2045(16)30166-8 10.1186/s40425-018-0378-y 10.1038/s41574-020-00465-y 10.1089/thy.2018.0509 10.3389/fimmu.2022.943916 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2023 The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. |
| DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.bbcan.2023.188928 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology |
| EISSN | 1879-2561 |
| EndPage | 188928 |
| ExternalDocumentID | 10_1016_j_bbcan_2023_188928 37257629 S0304419X2300077X |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6I. 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABEFU ABFNM ABGSF ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HLW HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR LX3 M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 PC. Q38 R2- ROL RPZ SAE SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K UQL WUQ XJT XPP ZE2 ~G- AAXKI AFJKZ AKRWK NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c404t-d58576a26776ccca229355614be7a8430e4ed1ada83f880d886e760c2840f89e3 |
| IEDL.DBID | AIKHN |
| ISSN | 0304-419X |
| IngestDate | Sat Oct 05 06:02:27 EDT 2024 Thu Sep 26 17:44:31 EDT 2024 Sat Sep 28 08:20:27 EDT 2024 Fri Feb 23 02:37:09 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Multi-tyrosine kinase inhibitors Immune checkpoint inhibitors Thyroid cancer |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c404t-d58576a26776ccca229355614be7a8430e4ed1ada83f880d886e760c2840f89e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0304419X2300077X |
| PMID | 37257629 |
| PQID | 2821639910 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_2821639910 crossref_primary_10_1016_j_bbcan_2023_188928 pubmed_primary_37257629 elsevier_sciencedirect_doi_10_1016_j_bbcan_2023_188928 |
| PublicationCentury | 2000 |
| PublicationDate | July 2023 2023-Jul 2023-07-00 20230701 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: July 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. Reviews on cancer |
| PublicationTitleAlternate | Biochim Biophys Acta Rev Cancer |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Takahashi, Kiyota, Yamazaki, Chayahara, Nakano, Inagaki, Toda, Enokida, Minami, Imamura, Fukuda, Sasaki, Suzuki, Ikezawa, Dutcus, Tahara (bb0390) 2019; 15 Iyer, Dadu, Gule-Monroe, Busaidy, Ferrarotto, Habra, Zafereo, Williams, Gunn, Grosu, Skinner, Sturgis, Gross, Cabanillas (bb0510) 2018; 6 Van Nostrand (bb0040) 2018; 28 Galrão, Camargo, Friguglietti, Moraes, Cerutti, Serrano-Nascimento, Suzuki, Medeiros-Neto, Rubio (bb0185) 2014; 99 Lin, Yang, Ding, Cheng, Shi, Tan, Deng, Chen, Wang, Ji, Huang, Li (bb0425) 2021; 31 Brose, Cabanillas, Cohen, Wirth, Riehl, Yue, Sherman, Sherman (bb0280) 2016; 17 Subbiah, Gainor, Rahal, Brubaker, Kim, Maynard, Hu, Cao, Sheets, Wilson, Wilson, DiPietro, Fleming, Palmer, Hu, Wirth, Brose, Ou, Taylor, Garralda, Miller, Wolf, Lengauer, Guzi, Evans (bb0380) 2018; 8 Wirth, Sherman, Robinson, Solomon, Kang, Lorch, Worden, Brose, Patel, Leboulleux, Godbert, Barlesi, Morris, Owonikoko, Tan, Gautschi, Weiss, de la Fouchardière, Burkard, Laskin, Taylor, Kroiss, Medioni, Goldman, Bauer, Levy, Zhu, Lakhani, Moreno, Ebata, Nguyen, Heirich, Zhu, Huang, Yang, Kherani, Rothenberg, Drilon, Subbiah, Shah, Cabanillas (bb0275) 2020; 383 Lin, Qin, Li, Yang, Fu, Li, Chen, Gao, Miao, Xu, Zhang, Zhao, Bao, Li, Ren, Lin, Jing, Ma, Liang, Chen, Zhang, Zhang, Zhou, Sang, Hou (bb0265) 2022; 8 Chen, Ji, Bai, Zheng, Zhang, Shi, Li, Tang, Xu, Huang, Huang, Pan, Fan, Zhou, Su (bb0420) 2020; 30 Siegel, Miller, Fuchs, Jemal (bb0005) 2021; 71 Xing (bb0120) 2005; 12 Moura, Cavaco, Leite (bb0145) 2015; 22 Hofstra, Landsvater, Ceccherini, Stulp, Stelwagen, Luo, Pasini, Höppener, van Amstel, Romeo (bb0155) 1994; 367 Al Rasheed, Xu (bb0350) 2019; 12 (bb0370) 2020; 10 Chen, Bao, Chen, Jia, Li, Zhang, Fan, Fang, Jin (bb0210) 2022; 2022 Barros-Filho, Dos Reis, Beltrami, de Mello, Marchi, Kuasne, Drigo, de Andrade, Saieg, Pinto, Kowalski, Rogatto (bb0175) 2019; 29 Xing (bb0080) 2013; 13 Varricchi, Loffredo, Marone, Modestino, Fallahi, Ferrari, de Paulis, Antonelli, Galdiero (bb0485) 2019; 20 Cabanillas, Ryder, Jimenez (bb0220) 2019; 40 Fallahi, Ferrari, Galdiero, Varricchi, Elia, Ragusa, Paparo, Benvenga, Antonelli (bb0020) 2022; 79 Hou, Ji, Xing (bb0160) 2008; 113 Cao, Zhang, Zhang, Lou, Zhou, Fang (bb0195) 2021; 496 de la Fouchardière, Godbert, Dalban, Illouz, Wassermann, Do Cao, Bardet, Zerdoud, Chougnet, Zalzali, Benisvy, Niccoli, Digue, Lamartina, Schwartz, Borson Chazot, Gautier, Pérol, Leboulleux (bb0430) 2021; 157 Rosen, Won, Zheng, Cocco, Selcuklu, Gong, Friedman, de Bruijn, Sumer, Bielski, Savin, Bourque, Falcon, Clarke, Jing, Meng, Zimel, Shifman, Kittane, Wu, Ladanyi, Ebata, Kherani, Brandhuber, Fagin, Sherman, Rekhtman, Berger, Scaltriti, Hyman, Taylor, Drilon (bb0460) 2022; 13 Saini, Tulla, Maker, Burman, Prabhakar (bb0055) 2018; 17 Lin, Zhang, Wang, Liu, Guan, Liang (bb0260) 2021; 106 Tahara, Kiyota, Yamazaki, Chayahara, Nakano, Inagaki, Toda, Enokida, Minami, Imamura, Sasaki, Suzuki, Fujino, Dutcus, Takahashi (bb0395) 2017; 7 Motoi, Sakamoto, Yamochi, Horiuchi, Motoi, Machinami (bb0135) 2000; 196 Busaidy, Konda, Wei, Wirth, Devine, Daniels, DeSouza, Poi, Seligson, Cabanillas, Sipos, Ringel, Eisfeld, Timmers, Shah (bb0285) 2022; 32 Kreissl, Bastholt, Elisei, Haddad, Hauch, Jarząb, Robinson, Colzani, Foster, Weiss, Schlumberger (bb0355) 2020; 38 Dierks, Seufert, Aumann, Ruf, Klein, Kiefer, Rassner, Boerries, Zielke, la Rosee, Meyer, Kroiss, Weißenberger, Schumacher, Metzger, Weiss, Smaxwil, Laubner, Duyster, von Bubnoff, Miething, Thomusch (bb0515) 2021; 31 Rothenberg, Daniels, Wirth (bb0300) 2015; 21 Rothenberg, McFadden, Palmer, Daniels, Wirth (bb0440) 2015; 21 Nervo, Retta, Ragni, Piovesan, Gallo, Arvat (bb0230) 2022; 14 Mehnert, Varga, Brose, Aggarwal, Lin, Prawira, de Braud, Tamura, Doi, Piha-Paul, Gilbert, Saraf, Thanigaimani, Cheng, Keam (bb0495) 2019; 19 Filetti, Durante, Hartl, Leboulleux, Locati, Newbold, Papotti, Berruti (bb0010) 2019; 30 Fleeman, Houten, Bagust, Richardson, Beale, Boland, Dundar, Greenhalgh, Hounsome, Duarte, Shenoy (bb0240) 2020; 24 Busaidy (bb0465) 2020; 30 Rosen, Johnson, Clifford, Somwar, Kherani, Son, Bertram, Davare, Gladstone, Ivanova, Henry, Kelley, Lin, Milan, Nair, Olek, Scanlon, Vojnic, Ebata, Hechtman, Li, Sholl, Taylor, Ladanyi, Jänne, Rothenberg, Drilon, Oxnard (bb0470) 2021; 27 Liu, Wang, Xiu, Wu, Xu (bb0180) 2021; 13 Waguespack, Drilon, Lin, Brose, McDermott, Almubarak, Bauman, Casanova, Krishnamurthy, Kummar, Leyvraz, Oh, Park, Sohal, Sherman, Norenberg, Silvertown, Brega, Hong, Cabanillas (bb0305) 2022; 186 Ciampi, Romei, Ramone, Prete, Tacito, Cappagli, Bottici, Viola, Torregrossa, Ugolini, Basolo, Elisei (bb0150) 2019; 20 Matrone, Gambale, Prete, Elisei (bb0050) 2022; 13 Maniakas, Dadu, Busaidy, Wang, Ferrarotto, Lu, Williams, Gunn, Hofmann, Cote, Sperling, Gross, Sturgis, Goepfert, Lai, Cabanillas, Zafereo (bb0060) 2020; 6 Brose, Robinson, Sherman, Krajewska, Lin, Vaisman, Hoff, Hitre, Bowles, Hernando, Faoro, Banerjee, Oliver, Keam, Capdevila (bb0250) 2021; 22 Zheng, Xu, Ji, Ge, Shi, Qin, Wang, Chen, Zhang, Huang, Tan, Huang, Li, Lv, Lin, Guo, Kubota, Suzuki, Ikezawa, Gao, Randomized (bb0225) 2021; 27 Savvides, Nagaiah, Lavertu, Fu, Wright, Chapman, Wasman, Dowlati, Remick (bb0410) 2013; 23 Subbiah, Kreitman, Wainberg, Cho, Schellens, Soria, Wen, Zielinski, Cabanillas, Urbanowitz, Mookerjee, Wang, Rangwala, Keam (bb0330) 2018; 36 Renaud, Gnemmi, Devos, Aubert, Crépin, Coppin, Ramdane, Bouchindhomme, d’Herbomez, Van Seuningen, Do Cao, Pattou, Carnaille, Pigny, Wémeau, Leteurtre (bb0110) 2014; 24 Nikiforov, Nikiforova (bb0085) 2011; 7 Di Molfetta, Dotto, Fanciulli, Florio, Feola, Colao, Faggiano (bb0075) 2021; 12 Gild, Tsang, Clifton-Bligh, Robinson (bb0065) 2021; 17 Brose, Nutting, Jarzab, Elisei, Siena, Bastholt, de la Fouchardiere, Pacini, Paschke, Shong, Sherman, Smit, Chung, Kappeler, Peña, Molnár, Schlumberger (bb0235) 2014; 384 Bastman, Serracino, Zhu, Koenig, Mateescu, Sams, Davies, Raeburn, McIntyre, Haugen, French (bb0490) 2016; 101 Wright, Powers, Johnson (bb0480) 2021; 17 Schlumberger, Leboulleux (bb0015) 2021; 17 Geng, Song, Li, Zhao (bb0255) 2018; 17 Zhu, Liu, Wang, Peng (bb0270) 2022; 13 Liu, Hou, Ji, Guan, Studeman, Jensen, Vasko, El-Naggar, Xing (bb0095) 2008; 93 Oh, Ahn (bb0205) 2021; 11 Kogai, Taki, Brent (bb0200) 2006; 13 Tappenden, Carroll, Hamilton, Kaltenthaler, Wong, Wadsley, Moss, Balasubramanian (bb0360) 2019; 23 Liu, Liu, Bojdani, El-Naggar, Vasko, Xing (bb0100) 2010; 16 Esapa, Johnson, Kendall-Taylor, Lennard, Harris (bb0140) 1999; 50 Zou, Baitei, Al-Rijjal, Parhar, Al-Mohanna, Kimura, Pritchard, Binessa, Alzahrani, Al-Khalaf, Hawwari, Akhtar, Assiri, Meyer, Shi (bb0125) 2016; 35 Schlumberger, Brose, Elisei, Leboulleux, Luster, Pitoia, Pacini (bb0045) 2014; 2 Addeo, Miranda-Morales, den Hollander, Friedlaender, Herman, Wu, Mani, Subbiah (bb0385) 2023; 242 Duke, Barone, Chatterjee, Mishra-Kalyani, Shen, Isikwei, Zhao, Bi, Liu, Rahman, Wearne, Leighton, Stephenson, Ojofeitimi, Scepura, Nair, Pazdur, Beaver, Singh (bb0245) 2022; 28 Haugen, Alexander, Bible, Doherty, Mandel, Nikiforov, Pacini, Randolph, Sawka, Schlumberger, Schuff, Sherman, Sosa, Steward, Tuttle, Wartofsky (bb0035) 2016; 26 Zheng, Cui, Zhang, Wang, Ming (bb0215) 2019; 10 Elisei, Schlumberger, Müller, Schöffski, Brose, Shah, Licitra, Jarzab, Medvedev, Kreissl, Niederle, Cohen, Wirth, Ali, Hessel, Yaron, Ball, Nelkin, Sherman (bb0315) 2013; 31 Dwight, Thoppe, Foukakis, Lui, Wallin, Höög, Frisk, Larsson, Zedenius (bb0170) 2003; 88 Li, Chi, Chen, Ge, Zhang, Guo, Wang, Chen, Zhang, Cheng, Li, Liu, Qin, Zhu, Cheng, Xu, Zheng, Tang, Gao (bb0325) 2021; 27 Lim, Chung, Nam, Kang, Lim, Kim, Shin, Sun, Kim, Kim, Kang, Kim, Cho (bb0415) 2015; 51 Gunda, Gigliotti, Ashry, Ndishabandi, McCarthy, Zhou, Amin, Lee, Stork, Wirth, Freeman, Alessandrini, Parangi (bb0505) 2019; 144 Vodopivec, Hu (bb0445) 2022; 14 Ricarte-Filho, Ryder, Chitale, Rivera, Heguy, Ladanyi, Janakiraman, Solit, Knauf, Tuttle, Ghossein, Fagin (bb0090) 2009; 69 Li, Zhang, Mu, Sun, Sun, Lin (bb0520) 2022; 13 Kouvaraki, Shapiro, Perrier, Cote, Gagel, Hoff, Sherman, Lee, Evans (bb0340) 2005; 15 Higashiyama, Sugino, Hara, Ito, Nakashima, Onoda, Tori, Katoh, Kiyota, Ota, Suganuma, Hibi, Nemoto, Takahashi, Yane, Ioji, Kojima, Kaneda, Sugitani, Tahara (bb0405) 2022; 173 Lee, Au, Foukakis, Barbaro, Kiss, Clifton-Bligh, Staaf, Borg, Delbridge, Robinson, Wallin, Höög, Larsson (bb0105) 2008; 15 Filetti, Durante, Hartl, Leboulleux, Locati, Newbold, Papotti, Berruti (bb0375) 2022; 33 Wirth, Brose, Sherman, Licitra, Schlumberger, Sherman, Bible, Robinson, Rodien, Godbert, De La Fouchardiere, Newbold, Nutting, Misir, Xie, Almonte, Ye, Cabanillas (bb0400) 2021; 39 Weng, He, Chen, Lin, Ji, Lu, Ao, Wang (bb0335) 2022; 13 Christofer Juhlin, Mete, Baloch (bb0025) 2023; 30 Beermann, Piccoli, Viereck, Thum (bb0190) 2016; 96 Subbiah, Hu, Wirth, Schuler, Mansfield, Curigliano, Brose, Zhu, Leboulleux, Bowles, Baik, Adkins, Keam, Matos, Garralda, Gainor, Lopes, Lin, Godbert, Sarker, Miller, Clifford, Zhang, Turner, Taylor (bb0320) 2021; 9 Frisco, Gunn, Thomas, Stang, Scheri, Kazaure (bb0450) 2023; 173 Liu, Gunda, Zhu, Xu, Wu, Askhatova, Farokhzad, Parangi, Shi (bb0525) 2016; 113 Subbiah, Velcheti, Tuch, Ebata, Busaidy, Cabanillas, Wirth, Stock, Smith, Lauriault, Corsi-Travali, Henry, Burkard, Hamor, Bouhana, Winski, Wallace, Hartley, Rhodes, Reddy, Brandhuber, Andrews, Rothenberg, Drilon (bb0365) 2018; 29 Saltiki, Simeakis, Karapanou, Alevizaki (bb0455) 2022; 187 Wells, Robinson, Gagel, Dralle, Fagin, Santoro, Baudin, Elisei, Jarzab, Vasselli, Read, Langmuir, Ryan, Schlumberger (bb0310) 2012; 30 Dunn, Sherman, Baxi, Tchekmedyian, Grewal, Larson, Pentlow, Haque, Tuttle, Sabra, Fish, Boucai, Walters, Ghossein, Seshan, Ni, Li, Knauf, Pfister, Fagin, Ho (bb0290) 2019; 104 Ibrahimpasic, Ghossein, Shah, Ganly (bb0030) 2019; 29 Tchekmedyian, Dunn, Sherman, Baxi, Grewal, Larson, Pentlow, Haque, Tuttle, Sabra, Fish, Boucai, Walters, Ghossein, Seshan, Knauf, Pfister, Fagin, Ho (bb0295) 2022; 32 Cancer Genome Atlas Research Network (bb0130) 2014; 15 Schlumberger (10.1016/j.bbcan.2023.188928_bb0045) 2014; 2 Bastman (10.1016/j.bbcan.2023.188928_bb0490) 2016; 101 Matrone (10.1016/j.bbcan.2023.188928_bb0050) 2022; 13 Wright (10.1016/j.bbcan.2023.188928_bb0480) 2021; 17 Dunn (10.1016/j.bbcan.2023.188928_bb0290) 2019; 104 Lee (10.1016/j.bbcan.2023.188928_bb0105) 2008; 15 Ricarte-Filho (10.1016/j.bbcan.2023.188928_bb0090) 2009; 69 Tappenden (10.1016/j.bbcan.2023.188928_bb0360) 2019; 23 Iyer (10.1016/j.bbcan.2023.188928_bb0510) 2018; 6 Barros-Filho (10.1016/j.bbcan.2023.188928_bb0175) 2019; 29 Elisei (10.1016/j.bbcan.2023.188928_bb0315) 2013; 31 Liu (10.1016/j.bbcan.2023.188928_bb0525) 2016; 113 Busaidy (10.1016/j.bbcan.2023.188928_bb0285) 2022; 32 Lim (10.1016/j.bbcan.2023.188928_bb0415) 2015; 51 Weng (10.1016/j.bbcan.2023.188928_bb0335) 2022; 13 Li (10.1016/j.bbcan.2023.188928_bb0325) 2021; 27 Cao (10.1016/j.bbcan.2023.188928_bb0195) 2021; 496 Rothenberg (10.1016/j.bbcan.2023.188928_bb0440) 2015; 21 Oh (10.1016/j.bbcan.2023.188928_bb0205) 2021; 11 Higashiyama (10.1016/j.bbcan.2023.188928_bb0405) 2022; 173 Fleeman (10.1016/j.bbcan.2023.188928_bb0240) 2020; 24 Mehnert (10.1016/j.bbcan.2023.188928_bb0495) 2019; 19 Zhu (10.1016/j.bbcan.2023.188928_bb0270) 2022; 13 Waguespack (10.1016/j.bbcan.2023.188928_bb0305) 2022; 186 Liu (10.1016/j.bbcan.2023.188928_bb0095) 2008; 93 Jiao (10.1016/j.bbcan.2023.188928_bb0070) 2018; 17 Dierks (10.1016/j.bbcan.2023.188928_bb0515) 2021; 31 Galrão (10.1016/j.bbcan.2023.188928_bb0185) 2014; 99 Addeo (10.1016/j.bbcan.2023.188928_bb0385) 2023; 242 Filetti (10.1016/j.bbcan.2023.188928_bb0010) 2019; 30 Kogai (10.1016/j.bbcan.2023.188928_bb0200) 2006; 13 Ciampi (10.1016/j.bbcan.2023.188928_bb0150) 2019; 20 Carling (10.1016/j.bbcan.2023.188928_bb0165) 2014; 65 Beermann (10.1016/j.bbcan.2023.188928_bb0190) 2016; 96 Frisco (10.1016/j.bbcan.2023.188928_bb0450) 2023; 173 Varricchi (10.1016/j.bbcan.2023.188928_bb0485) 2019; 20 Maniakas (10.1016/j.bbcan.2023.188928_bb0060) 2020; 6 Haugen (10.1016/j.bbcan.2023.188928_bb0035) 2016; 26 Xing (10.1016/j.bbcan.2023.188928_bb0080) 2013; 13 Subbiah (10.1016/j.bbcan.2023.188928_bb0330) 2018; 36 Saini (10.1016/j.bbcan.2023.188928_bb0055) 2018; 17 Vodopivec (10.1016/j.bbcan.2023.188928_bb0445) 2022; 14 Filetti (10.1016/j.bbcan.2023.188928_bb0375) 2022; 33 Liu (10.1016/j.bbcan.2023.188928_bb0100) 2010; 16 Schlumberger (10.1016/j.bbcan.2023.188928_bb0015) 2021; 17 Rothenberg (10.1016/j.bbcan.2023.188928_bb0300) 2015; 21 Brose (10.1016/j.bbcan.2023.188928_bb0235) 2014; 384 Subbiah (10.1016/j.bbcan.2023.188928_bb0380) 2018; 8 Tahara (10.1016/j.bbcan.2023.188928_bb0395) 2017; 7 Lin (10.1016/j.bbcan.2023.188928_bb0425) 2021; 31 Zheng (10.1016/j.bbcan.2023.188928_bb0215) 2019; 10 Moura (10.1016/j.bbcan.2023.188928_bb0145) 2015; 22 Liu (10.1016/j.bbcan.2023.188928_bb0180) 2021; 13 Kouvaraki (10.1016/j.bbcan.2023.188928_bb0340) 2005; 15 Esapa (10.1016/j.bbcan.2023.188928_bb0140) 1999; 50 Christofer Juhlin (10.1016/j.bbcan.2023.188928_bb0025) 2023; 30 Fallahi (10.1016/j.bbcan.2023.188928_bb0020) 2022; 79 Ibrahimpasic (10.1016/j.bbcan.2023.188928_bb0030) 2019; 29 Tchekmedyian (10.1016/j.bbcan.2023.188928_bb0295) 2022; 32 Chen (10.1016/j.bbcan.2023.188928_bb0210) 2022; 2022 Renaud (10.1016/j.bbcan.2023.188928_bb0110) 2014; 24 Nervo (10.1016/j.bbcan.2023.188928_bb0230) 2022; 14 Saltiki (10.1016/j.bbcan.2023.188928_bb0455) 2022; 187 Lin (10.1016/j.bbcan.2023.188928_bb0260) 2021; 106 Román-Gil (10.1016/j.bbcan.2023.188928_bb0475) 2022; 105 Dwight (10.1016/j.bbcan.2023.188928_bb0170) 2003; 88 Di Molfetta (10.1016/j.bbcan.2023.188928_bb0075) 2021; 12 Brose (10.1016/j.bbcan.2023.188928_bb0250) 2021; 22 Brose (10.1016/j.bbcan.2023.188928_bb0280) 2016; 17 Zheng (10.1016/j.bbcan.2023.188928_bb0225) 2021; 27 Duke (10.1016/j.bbcan.2023.188928_bb0245) 2022; 28 Lin (10.1016/j.bbcan.2023.188928_bb0265) 2022; 8 Kimura (10.1016/j.bbcan.2023.188928_bb0115) 2003; 63 Rosen (10.1016/j.bbcan.2023.188928_bb0470) 2021; 27 Motoi (10.1016/j.bbcan.2023.188928_bb0135) 2000; 196 Geng (10.1016/j.bbcan.2023.188928_bb0255) 2018; 17 (10.1016/j.bbcan.2023.188928_bb0370) 2020; 10 Wirth (10.1016/j.bbcan.2023.188928_bb0400) 2021; 39 Wells (10.1016/j.bbcan.2023.188928_bb0310) 2012; 30 Nikiforov (10.1016/j.bbcan.2023.188928_bb0085) 2011; 7 Cabanillas (10.1016/j.bbcan.2023.188928_bb0435) 2017; 35 Hou (10.1016/j.bbcan.2023.188928_bb0160) 2008; 113 Xing (10.1016/j.bbcan.2023.188928_bb0120) 2005; 12 de la Fouchardière (10.1016/j.bbcan.2023.188928_bb0430) 2021; 157 Subbiah (10.1016/j.bbcan.2023.188928_bb0320) 2021; 9 Gunda (10.1016/j.bbcan.2023.188928_bb0500) 2018; 119 Rosen (10.1016/j.bbcan.2023.188928_bb0460) 2022; 13 Chen (10.1016/j.bbcan.2023.188928_bb0420) 2020; 30 Cancer Genome Atlas Research Network (10.1016/j.bbcan.2023.188928_bb0130) 2014; 159 Savvides (10.1016/j.bbcan.2023.188928_bb0410) 2013; 23 Siegel (10.1016/j.bbcan.2023.188928_bb0005) 2021; 71 Van Nostrand (10.1016/j.bbcan.2023.188928_bb0040) 2018; 28 Wirth (10.1016/j.bbcan.2023.188928_bb0275) 2020; 383 Hofstra (10.1016/j.bbcan.2023.188928_bb0155) 1994; 367 Subbiah (10.1016/j.bbcan.2023.188928_bb0365) 2018; 29 Gunda (10.1016/j.bbcan.2023.188928_bb0505) 2019; 144 Cabanillas (10.1016/j.bbcan.2023.188928_bb0220) 2019; 40 Gild (10.1016/j.bbcan.2023.188928_bb0065) 2021; 17 Kreissl (10.1016/j.bbcan.2023.188928_bb0355) 2020; 38 Busaidy (10.1016/j.bbcan.2023.188928_bb0465) 2020; 30 Zou (10.1016/j.bbcan.2023.188928_bb0125) 2016; 35 Al Rasheed (10.1016/j.bbcan.2023.188928_bb0350) 2019; 12 Takahashi (10.1016/j.bbcan.2023.188928_bb0390) 2019; 15 Li (10.1016/j.bbcan.2023.188928_bb0520) 2022; 13 Capp (10.1016/j.bbcan.2023.188928_bb0345) 2010; 20 |
| References_xml | – volume: 31 start-page: 3639 year: 2013 end-page: 3646 ident: bb0315 article-title: Cabozantinib in progressive medullary thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Sherman – volume: 13 start-page: 184 year: 2013 end-page: 199 ident: bb0080 article-title: Molecular pathogenesis and mechanisms of thyroid cancer publication-title: Nat. Rev. Cancer contributor: fullname: Xing – volume: 20 start-page: 324 year: 2019 end-page: 336 ident: bb0150 article-title: Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing publication-title: iScience contributor: fullname: Elisei – volume: 35 start-page: 1909 year: 2016 end-page: 1918 ident: bb0125 article-title: TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer publication-title: Oncogene contributor: fullname: Shi – volume: 119 start-page: 1223 year: 2018 end-page: 1232 ident: bb0500 article-title: Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer publication-title: Br. J. Cancer contributor: fullname: Parangi – volume: 187 start-page: R53 year: 2022 end-page: r63 ident: bb0455 article-title: MANAGEMENT OF ENDOCRINE DISEASE: medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives publication-title: Eur. J. Endocrinol. contributor: fullname: Alevizaki – volume: 6 start-page: 68 year: 2018 ident: bb0510 article-title: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma publication-title: J. Immunother. Cancer contributor: fullname: Cabanillas – volume: 196 start-page: 1 year: 2000 end-page: 7 ident: bb0135 article-title: Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin publication-title: Pathol. Res. Pract. contributor: fullname: Machinami – volume: 24 start-page: 1375 year: 2014 end-page: 1384 ident: bb0110 article-title: MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Leteurtre – volume: 30 start-page: 13 year: 2020 end-page: 19 ident: bb0465 article-title: The year in medical thyroidology review: current challenges and future directions publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Busaidy – volume: 13 start-page: 864253 year: 2022 ident: bb0050 article-title: Sporadic medullary thyroid carcinoma: towards a precision medicine publication-title: Front. Endocrinol. contributor: fullname: Elisei – volume: 6 start-page: 1397 year: 2020 end-page: 1404 ident: bb0060 article-title: Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019 publication-title: JAMA Oncol. contributor: fullname: Zafereo – volume: 28 start-page: 4173 year: 2022 end-page: 4177 ident: bb0245 article-title: FDA approval summary: cabozantinib for differentiated thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Singh – volume: 27 start-page: 3567 year: 2021 end-page: 3575 ident: bb0325 article-title: Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Gao – volume: 32 start-page: 1184 year: 2022 end-page: 1192 ident: bb0285 article-title: Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Shah – volume: 105 start-page: 102372 year: 2022 ident: bb0475 article-title: Resistance to RET targeted therapy in thyroid cancer: molecular basis and overcoming strategies publication-title: Cancer Treat. Rev. contributor: fullname: Alonso-Gordoa – volume: 30 start-page: 1856 year: 2019 end-page: 1883 ident: bb0010 article-title: Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up† publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. contributor: fullname: Berruti – volume: 16 start-page: 6009 year: 2010 end-page: 6018 ident: bb0100 article-title: IQGAP1 plays an important role in the invasiveness of thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Xing – volume: 19 start-page: 196 year: 2019 ident: bb0495 article-title: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer publication-title: BMC Cancer contributor: fullname: Keam – volume: 14 start-page: 3047 year: 2022 end-page: 3062 ident: bb0230 article-title: Management of progressive radioiodine-refractory thyroid carcinoma: current perspective publication-title: Cancer Manag. Res. contributor: fullname: Arvat – volume: 17 start-page: 1145 year: 2018 end-page: 1150 ident: bb0255 article-title: The safety of apatinib for the treatment of gastric cancer publication-title: Expert Opin. Drug Saf. contributor: fullname: Zhao – volume: 104 start-page: 1417 year: 2019 end-page: 1428 ident: bb0290 article-title: Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Ho – volume: 29 start-page: 1869 year: 2018 end-page: 1876 ident: bb0365 article-title: Selective RET kinase inhibition for patients with RET-altered cancers publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. contributor: fullname: Drilon – volume: 10 start-page: 421 year: 2019 ident: bb0215 article-title: Leukocyte mitochondrial DNA copy number and risk of thyroid cancer: a two-stage case-control study publication-title: Front. Endocrinol. contributor: fullname: Ming – volume: 15 start-page: 531 year: 2005 end-page: 544 ident: bb0340 article-title: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Evans – volume: 17 start-page: 154 year: 2018 ident: bb0055 article-title: Therapeutic advances in anaplastic thyroid cancer: a current perspective publication-title: Mol. Cancer contributor: fullname: Prabhakar – volume: 173 start-page: 260 year: 2023 end-page: 267 ident: bb0450 article-title: Medullary thyroid cancer with RET V804M mutation: more indolent than expected? publication-title: Surgery contributor: fullname: Kazaure – volume: 65 start-page: 125 year: 2014 end-page: 137 ident: bb0165 article-title: Thyroid cancer publication-title: Annu. Rev. Med. contributor: fullname: Udelsman – volume: 8 start-page: 242 year: 2022 end-page: 250 ident: bb0265 article-title: Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial publication-title: JAMA Oncol. contributor: fullname: Hou – volume: 24 start-page: 1 year: 2020 end-page: 180 ident: bb0240 article-title: Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation publication-title: Health Technol. Assess. (Winchester, England) contributor: fullname: Shenoy – volume: 50 start-page: 529 year: 1999 end-page: 535 ident: bb0140 article-title: Prevalence of Ras mutations in thyroid neoplasia publication-title: Clin. Endocrinol. contributor: fullname: Harris – volume: 23 start-page: 600 year: 2013 end-page: 604 ident: bb0410 article-title: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Remick – volume: 30 start-page: 1245 year: 2020 end-page: 1253 ident: bb0420 article-title: Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Su – volume: 27 start-page: 34 year: 2021 end-page: 42 ident: bb0470 article-title: Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung Cancer by combining Selpercatinib with Crizotinib publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Oxnard – volume: 13 start-page: 909333 year: 2022 ident: bb0270 article-title: Vascular endothelial growth factor receptor inhibitors in Chinese patients with advanced radioactive iodine-refractory differentiated thyroid cancer: a network meta-analysis and cost-effectiveness analysis publication-title: Front. Endocrinol. contributor: fullname: Peng – volume: 27 start-page: 5502 year: 2021 end-page: 5509 ident: bb0225 article-title: Phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Randomized – volume: 367 start-page: 375 year: 1994 end-page: 376 ident: bb0155 article-title: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma publication-title: Nature contributor: fullname: Romeo – volume: 7 start-page: 25 year: 2017 ident: bb0395 article-title: Lenvatinib for anaplastic thyroid cancer publication-title: Front. Oncol. contributor: fullname: Takahashi – volume: 173 start-page: 210 year: 2022 end-page: 218 ident: bb0405 article-title: Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE) publication-title: Eur. J. Cancer (Oxford, England: 1990) contributor: fullname: Tahara – volume: 496 start-page: 117 year: 2021 end-page: 126 ident: bb0195 article-title: Non-coding RNA in thyroid cancer - functions and mechanisms publication-title: Cancer Lett. contributor: fullname: Fang – volume: 12 start-page: 245 year: 2005 end-page: 262 ident: bb0120 article-title: BRAF mutation in thyroid cancer publication-title: Endocr. Relat. Cancer contributor: fullname: Xing – volume: 7 start-page: 569 year: 2011 end-page: 580 ident: bb0085 article-title: Molecular genetics and diagnosis of thyroid cancer publication-title: Nat. Rev. Endocrinol. contributor: fullname: Nikiforova – volume: 2 start-page: 356 year: 2014 end-page: 358 ident: bb0045 article-title: Definition and management of radioactive iodine-refractory differentiated thyroid cancer publication-title: Lancet Diabetes Endocrinol. contributor: fullname: Pacini – volume: 106 start-page: e3027 year: 2021 end-page: e3036 ident: bb0260 article-title: Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Liang – volume: 186 start-page: 631 year: 2022 end-page: 643 ident: bb0305 article-title: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma publication-title: Eur. J. Endocrinol. contributor: fullname: Cabanillas – volume: 10 year: 2020 ident: bb0370 publication-title: FDA approves selpercatinib; pralsetinib may soon follow – volume: 21 start-page: 1028 year: 2015 end-page: 1035 ident: bb0440 article-title: Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Wirth – volume: 51 start-page: 1588 year: 2015 end-page: 1595 ident: bb0415 article-title: An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer publication-title: Eur. J. Cancer (Oxford, England: 1990) contributor: fullname: Cho – volume: 99 start-page: E944 year: 2014 end-page: E952 ident: bb0185 article-title: Hypermethylation of a new distal sodium/iodide symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Rubio – volume: 15 start-page: 717 year: 2019 end-page: 726 ident: bb0390 article-title: A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer publication-title: Future Oncol. (London, England) contributor: fullname: Tahara – volume: 71 start-page: 7 year: 2021 end-page: 33 ident: bb0005 article-title: Cancer statistics, 2021 publication-title: CA Cancer J. Clin. contributor: fullname: Jemal – volume: 144 start-page: 2266 year: 2019 end-page: 2278 ident: bb0505 article-title: Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer publication-title: Int. J. Cancer contributor: fullname: Parangi – volume: 17 start-page: 1272 year: 2016 end-page: 1282 ident: bb0280 article-title: Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol. contributor: fullname: Sherman – volume: 88 start-page: 4440 year: 2003 end-page: 4445 ident: bb0170 article-title: Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Zedenius – volume: 8 start-page: 836 year: 2018 end-page: 849 ident: bb0380 article-title: Precision targeted therapy with BLU-667 for RET-driven cancers publication-title: Cancer Discov. contributor: fullname: Evans – volume: 29 start-page: 1244 year: 2019 end-page: 1254 ident: bb0175 article-title: DNA methylation-based method to differentiate malignant from benign thyroid lesions publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Rogatto – volume: 12 start-page: 667784 year: 2021 ident: bb0075 article-title: Immune checkpoint inhibitors: new weapons against medullary thyroid Cancer? publication-title: Front. Endocrinol. contributor: fullname: Faggiano – volume: 17 start-page: 36 year: 2018 ident: bb0070 article-title: Advances in studies of tyrosine kinase inhibitors and their acquired resistance publication-title: Mol. Cancer contributor: fullname: Wang – volume: 2022 start-page: 9982449 year: 2022 ident: bb0210 article-title: Thyroid cancer-associated mitochondrial DNA mutation G3842A promotes tumorigenicity via ROS-mediated ERK1/2 activation publication-title: Oxidative Med. Cell. Longev. contributor: fullname: Jin – volume: 13 start-page: 1055412 year: 2022 ident: bb0335 article-title: Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma publication-title: Front. Immunol. contributor: fullname: Wang – volume: 31 start-page: 607 year: 2021 end-page: 615 ident: bb0425 article-title: Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Li – volume: 9 start-page: 491 year: 2021 end-page: 501 ident: bb0320 article-title: Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study publication-title: Lancet Diabetes Endocrinol. contributor: fullname: Taylor – volume: 96 start-page: 1297 year: 2016 end-page: 1325 ident: bb0190 article-title: Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches publication-title: Physiol. Rev. contributor: fullname: Thum – volume: 35 start-page: 3315 year: 2017 end-page: 3321 ident: bb0435 article-title: Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Shah – volume: 11 start-page: 6251 year: 2021 end-page: 6277 ident: bb0205 article-title: Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS publication-title: Theranostics contributor: fullname: Ahn – volume: 23 start-page: 1 year: 2019 end-page: 144 ident: bb0360 article-title: Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model publication-title: Health Technol. Assess. (Winchester, England) contributor: fullname: Balasubramanian – volume: 17 start-page: 225 year: 2021 end-page: 234 ident: bb0065 article-title: Multikinase inhibitors in thyroid cancer: timing of targeted therapy publication-title: Nat. Rev. Endocrinol. contributor: fullname: Robinson – volume: 93 start-page: 3106 year: 2008 end-page: 3116 ident: bb0095 article-title: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Xing – volume: 157 start-page: 153 year: 2021 end-page: 164 ident: bb0430 article-title: intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: final results of the randomised, multicenter, open-label phase II trial PAZOTHYR publication-title: Eur. J. Cancer (Oxford, England: 1990) contributor: fullname: Leboulleux – volume: 20 year: 2019 ident: bb0485 article-title: The immune landscape of thyroid cancer in the context of immune checkpoint inhibition publication-title: Int. J. Mol. Sci. contributor: fullname: Galdiero – volume: 79 start-page: 180 year: 2022 end-page: 196 ident: bb0020 article-title: Molecular targets of tyrosine kinase inhibitors in thyroid cancer publication-title: Semin. Cancer Biol. contributor: fullname: Antonelli – volume: 30 year: 2023 ident: bb0025 article-title: The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading publication-title: Endocr. Relat. Cancer contributor: fullname: Baloch – volume: 12 start-page: 921 year: 2019 end-page: 930 ident: bb0350 article-title: Molecular alterations in thyroid carcinoma publication-title: Surgical Pathol. Clin. contributor: fullname: Xu – volume: 13 start-page: 943916 year: 2022 ident: bb0520 article-title: Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: a case report and literature review publication-title: Front. Immunol. contributor: fullname: Lin – volume: 32 start-page: 273 year: 2022 end-page: 282 ident: bb0295 article-title: Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Ho – volume: 17 start-page: 389 year: 2021 end-page: 399 ident: bb0480 article-title: Endocrine toxicities of immune checkpoint inhibitors publication-title: Nat. Rev. Endocrinol. contributor: fullname: Johnson – volume: 384 start-page: 319 year: 2014 end-page: 328 ident: bb0235 article-title: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial publication-title: Lancet (London, England) contributor: fullname: Schlumberger – volume: 36 start-page: 7 year: 2018 end-page: 13 ident: bb0330 article-title: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Keam – volume: 113 start-page: 2440 year: 2008 end-page: 2447 ident: bb0160 article-title: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors publication-title: Cancer contributor: fullname: Xing – volume: 13 start-page: 1450 year: 2022 ident: bb0460 article-title: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers publication-title: Nat. Commun. contributor: fullname: Drilon – volume: 159 start-page: 676 year: 2014 end-page: 690 ident: bb0130 article-title: Integrated genomic characterization of papillary thyroid carcinoma publication-title: Cell contributor: fullname: Cancer Genome Atlas Research Network – volume: 28 start-page: 1083 year: 2018 end-page: 1093 ident: bb0040 article-title: Radioiodine refractory differentiated thyroid cancer: time to update the classifications publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Van Nostrand – volume: 22 start-page: R235 year: 2015 end-page: R252 ident: bb0145 article-title: RAS proto-oncogene in medullary thyroid carcinoma publication-title: Endocr. Relat. Cancer contributor: fullname: Leite – volume: 21 start-page: 5640 year: 2015 end-page: 5641 ident: bb0300 article-title: Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib-response publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. contributor: fullname: Wirth – volume: 101 start-page: 2863 year: 2016 end-page: 2873 ident: bb0490 article-title: Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: French – volume: 29 start-page: 311 year: 2019 end-page: 321 ident: bb0030 article-title: Poorly differentiated carcinoma of the thyroid gland: current status and future prospects publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Ganly – volume: 383 start-page: 825 year: 2020 end-page: 835 ident: bb0275 article-title: Efficacy of selpercatinib in RET-altered thyroid cancers publication-title: N. Engl. J. Med. contributor: fullname: Cabanillas – volume: 26 start-page: 1 year: 2016 end-page: 133 ident: bb0035 article-title: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Wartofsky – volume: 22 start-page: 1126 year: 2021 end-page: 1138 ident: bb0250 article-title: Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol. contributor: fullname: Capdevila – volume: 242 start-page: 108344 year: 2023 ident: bb0385 article-title: RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives publication-title: Pharmacol. Ther. contributor: fullname: Subbiah – volume: 63 start-page: 1454 year: 2003 end-page: 1457 ident: bb0115 article-title: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma publication-title: Cancer Res. contributor: fullname: Fagin – volume: 13 start-page: 797 year: 2006 end-page: 826 ident: bb0200 article-title: Enhancement of sodium/iodide symporter expression in thyroid and breast cancer publication-title: Endocr. Relat. Cancer contributor: fullname: Brent – volume: 30 start-page: 134 year: 2012 end-page: 141 ident: bb0310 article-title: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Schlumberger – volume: 15 start-page: 801 year: 2008 end-page: 815 ident: bb0105 article-title: Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma publication-title: Endocr. Relat. Cancer contributor: fullname: Larsson – volume: 20 start-page: 863 year: 2010 end-page: 871 ident: bb0345 article-title: Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Maia – volume: 38 start-page: 2773 year: 2020 end-page: 2781 ident: bb0355 article-title: Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Schlumberger – volume: 33 start-page: 674 year: 2022 end-page: 684 ident: bb0375 article-title: ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. contributor: fullname: Berruti – volume: 113 start-page: 7750 year: 2016 end-page: 7755 ident: bb0525 article-title: Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer publication-title: Proc. Natl. Acad. Sci. U. S. A. contributor: fullname: Shi – volume: 17 start-page: 176 year: 2021 end-page: 188 ident: bb0015 article-title: Current practice in patients with differentiated thyroid cancer publication-title: Nat. Rev. Endocrinol. contributor: fullname: Leboulleux – volume: 69 start-page: 4885 year: 2009 end-page: 4893 ident: bb0090 article-title: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 publication-title: Cancer Res. contributor: fullname: Fagin – volume: 13 year: 2021 ident: bb0180 article-title: DNA methylation age drift is associated with poor outcomes and de-differentiation in papillary and follicular thyroid carcinomas publication-title: Cancers contributor: fullname: Xu – volume: 40 start-page: 1573 year: 2019 end-page: 1604 ident: bb0220 article-title: Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond publication-title: Endocr. Rev. contributor: fullname: Jimenez – volume: 31 start-page: 1076 year: 2021 end-page: 1085 ident: bb0515 article-title: Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Thomusch – volume: 39 start-page: 2359 year: 2021 end-page: 2366 ident: bb0400 article-title: Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. contributor: fullname: Cabanillas – volume: 14 year: 2022 ident: bb0445 article-title: RET kinase inhibitors for RET-altered thyroid cancers publication-title: Ther. Adv. Med. Oncol. contributor: fullname: Hu – volume: 20 start-page: 863 issue: 8 year: 2010 ident: 10.1016/j.bbcan.2023.188928_bb0345 article-title: Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2009.0417 contributor: fullname: Capp – volume: 11 start-page: 6251 issue: 13 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0205 article-title: Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS publication-title: Theranostics doi: 10.7150/thno.57689 contributor: fullname: Oh – volume: 15 start-page: 801 issue: 3 year: 2008 ident: 10.1016/j.bbcan.2023.188928_bb0105 article-title: Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma publication-title: Endocr. Relat. Cancer doi: 10.1677/ERC-08-0018 contributor: fullname: Lee – volume: 13 start-page: 797 issue: 3 year: 2006 ident: 10.1016/j.bbcan.2023.188928_bb0200 article-title: Enhancement of sodium/iodide symporter expression in thyroid and breast cancer publication-title: Endocr. Relat. Cancer doi: 10.1677/erc.1.01143 contributor: fullname: Kogai – volume: 144 start-page: 2266 issue: 9 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0505 article-title: Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.32041 contributor: fullname: Gunda – volume: 2022 start-page: 9982449 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0210 article-title: Thyroid cancer-associated mitochondrial DNA mutation G3842A promotes tumorigenicity via ROS-mediated ERK1/2 activation publication-title: Oxidative Med. Cell. Longev. contributor: fullname: Chen – volume: 20 start-page: 324 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0150 article-title: Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing publication-title: iScience doi: 10.1016/j.isci.2019.09.030 contributor: fullname: Ciampi – volume: 496 start-page: 117 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0195 article-title: Non-coding RNA in thyroid cancer - functions and mechanisms publication-title: Cancer Lett. doi: 10.1016/j.canlet.2020.08.021 contributor: fullname: Cao – volume: 2 start-page: 356 issue: 5 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0045 article-title: Definition and management of radioactive iodine-refractory differentiated thyroid cancer publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(13)70215-8 contributor: fullname: Schlumberger – volume: 39 start-page: 2359 issue: 21 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0400 article-title: Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.20.03093 contributor: fullname: Wirth – volume: 113 start-page: 2440 issue: 9 year: 2008 ident: 10.1016/j.bbcan.2023.188928_bb0160 article-title: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors publication-title: Cancer doi: 10.1002/cncr.23869 contributor: fullname: Hou – volume: 8 start-page: 836 issue: 7 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0380 article-title: Precision targeted therapy with BLU-667 for RET-driven cancers publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-0338 contributor: fullname: Subbiah – volume: 104 start-page: 1417 issue: 5 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0290 article-title: Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2018-01478 contributor: fullname: Dunn – volume: 15 start-page: 531 issue: 6 year: 2005 ident: 10.1016/j.bbcan.2023.188928_bb0340 article-title: RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2005.15.531 contributor: fullname: Kouvaraki – volume: 26 start-page: 1 issue: 1 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0035 article-title: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2015.0020 contributor: fullname: Haugen – volume: 30 issue: 2 year: 2023 ident: 10.1016/j.bbcan.2023.188928_bb0025 article-title: The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-22-0293 contributor: fullname: Christofer Juhlin – volume: 17 start-page: 1145 issue: 11 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0255 article-title: The safety of apatinib for the treatment of gastric cancer publication-title: Expert Opin. Drug Saf. doi: 10.1080/14740338.2018.1535592 contributor: fullname: Geng – volume: 17 start-page: 176 issue: 3 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0015 article-title: Current practice in patients with differentiated thyroid cancer publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-020-00448-z contributor: fullname: Schlumberger – volume: 8 start-page: 242 issue: 2 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0265 article-title: Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2021.6268 contributor: fullname: Lin – volume: 12 start-page: 667784 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0075 article-title: Immune checkpoint inhibitors: new weapons against medullary thyroid Cancer? publication-title: Front. Endocrinol. doi: 10.3389/fendo.2021.667784 contributor: fullname: Di Molfetta – volume: 22 start-page: R235 issue: 5 year: 2015 ident: 10.1016/j.bbcan.2023.188928_bb0145 article-title: RAS proto-oncogene in medullary thyroid carcinoma publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-15-0070 contributor: fullname: Moura – volume: 99 start-page: E944 issue: 6 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0185 article-title: Hypermethylation of a new distal sodium/iodide symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2013-1450 contributor: fullname: Galrão – volume: 31 start-page: 1076 issue: 7 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0515 article-title: Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2020.0322 contributor: fullname: Dierks – volume: 24 start-page: 1375 issue: 9 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0110 article-title: MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2013.0594 contributor: fullname: Renaud – volume: 51 start-page: 1588 issue: 12 year: 2015 ident: 10.1016/j.bbcan.2023.188928_bb0415 article-title: An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer publication-title: Eur. J. Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2015.05.020 contributor: fullname: Lim – volume: 242 start-page: 108344 year: 2023 ident: 10.1016/j.bbcan.2023.188928_bb0385 article-title: RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2023.108344 contributor: fullname: Addeo – volume: 7 start-page: 25 year: 2017 ident: 10.1016/j.bbcan.2023.188928_bb0395 article-title: Lenvatinib for anaplastic thyroid cancer publication-title: Front. Oncol. doi: 10.3389/fonc.2017.00025 contributor: fullname: Tahara – volume: 50 start-page: 529 issue: 4 year: 1999 ident: 10.1016/j.bbcan.2023.188928_bb0140 article-title: Prevalence of Ras mutations in thyroid neoplasia publication-title: Clin. Endocrinol. doi: 10.1046/j.1365-2265.1999.00704.x contributor: fullname: Esapa – volume: 32 start-page: 273 issue: 3 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0295 article-title: Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2021.0565 contributor: fullname: Tchekmedyian – volume: 27 start-page: 34 issue: 1 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0470 article-title: Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung Cancer by combining Selpercatinib with Crizotinib publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-20-2278 contributor: fullname: Rosen – volume: 88 start-page: 4440 issue: 9 year: 2003 ident: 10.1016/j.bbcan.2023.188928_bb0170 article-title: Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2002-021690 contributor: fullname: Dwight – volume: 10 start-page: 421 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0215 article-title: Leukocyte mitochondrial DNA copy number and risk of thyroid cancer: a two-stage case-control study publication-title: Front. Endocrinol. doi: 10.3389/fendo.2019.00421 contributor: fullname: Zheng – volume: 105 start-page: 102372 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0475 article-title: Resistance to RET targeted therapy in thyroid cancer: molecular basis and overcoming strategies publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2022.102372 contributor: fullname: Román-Gil – volume: 14 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0445 article-title: RET kinase inhibitors for RET-altered thyroid cancers publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/17588359221101691 contributor: fullname: Vodopivec – volume: 71 start-page: 7 issue: 1 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0005 article-title: Cancer statistics, 2021 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21654 contributor: fullname: Siegel – volume: 6 start-page: 1397 issue: 9 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0060 article-title: Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.3362 contributor: fullname: Maniakas – volume: 29 start-page: 1244 issue: 9 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0175 article-title: DNA methylation-based method to differentiate malignant from benign thyroid lesions publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2018.0458 contributor: fullname: Barros-Filho – volume: 30 start-page: 1245 issue: 9 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0420 article-title: Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2019.0453 contributor: fullname: Chen – volume: 69 start-page: 4885 issue: 11 year: 2009 ident: 10.1016/j.bbcan.2023.188928_bb0090 article-title: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-0727 contributor: fullname: Ricarte-Filho – volume: 10 issue: 7 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0370 publication-title: Cancer Discov. – volume: 35 start-page: 3315 issue: 29 year: 2017 ident: 10.1016/j.bbcan.2023.188928_bb0435 article-title: Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2017.73.0226 contributor: fullname: Cabanillas – volume: 24 start-page: 1 issue: 2 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0240 article-title: Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation publication-title: Health Technol. Assess. (Winchester, England) doi: 10.3310/hta24020 contributor: fullname: Fleeman – volume: 13 start-page: 1450 issue: 1 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0460 article-title: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers publication-title: Nat. Commun. doi: 10.1038/s41467-022-28848-x contributor: fullname: Rosen – volume: 196 start-page: 1 issue: 1 year: 2000 ident: 10.1016/j.bbcan.2023.188928_bb0135 article-title: Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin publication-title: Pathol. Res. Pract. doi: 10.1016/S0344-0338(00)80015-1 contributor: fullname: Motoi – volume: 31 start-page: 607 issue: 4 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0425 article-title: Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2020.0235 contributor: fullname: Lin – volume: 28 start-page: 1083 issue: 9 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0040 article-title: Radioiodine refractory differentiated thyroid cancer: time to update the classifications publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2018.0048 contributor: fullname: Van Nostrand – volume: 13 start-page: 184 issue: 3 year: 2013 ident: 10.1016/j.bbcan.2023.188928_bb0080 article-title: Molecular pathogenesis and mechanisms of thyroid cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3431 contributor: fullname: Xing – volume: 63 start-page: 1454 issue: 7 year: 2003 ident: 10.1016/j.bbcan.2023.188928_bb0115 article-title: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma publication-title: Cancer Res. contributor: fullname: Kimura – volume: 27 start-page: 3567 issue: 13 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0325 article-title: Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-20-2950 contributor: fullname: Li – volume: 35 start-page: 1909 issue: 15 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0125 article-title: TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer publication-title: Oncogene doi: 10.1038/onc.2015.253 contributor: fullname: Zou – volume: 23 start-page: 600 issue: 5 year: 2013 ident: 10.1016/j.bbcan.2023.188928_bb0410 article-title: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2012.0103 contributor: fullname: Savvides – volume: 101 start-page: 2863 issue: 7 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0490 article-title: Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2015-4227 contributor: fullname: Bastman – volume: 173 start-page: 210 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0405 article-title: Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE) publication-title: Eur. J. Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2022.06.044 contributor: fullname: Higashiyama – volume: 40 start-page: 1573 issue: 6 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0220 article-title: Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond publication-title: Endocr. Rev. doi: 10.1210/er.2019-00007 contributor: fullname: Cabanillas – volume: 13 start-page: 864253 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0050 article-title: Sporadic medullary thyroid carcinoma: towards a precision medicine publication-title: Front. Endocrinol. doi: 10.3389/fendo.2022.864253 contributor: fullname: Matrone – volume: 9 start-page: 491 issue: 8 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0320 article-title: Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(21)00120-0 contributor: fullname: Subbiah – volume: 12 start-page: 921 issue: 4 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0350 article-title: Molecular alterations in thyroid carcinoma publication-title: Surgical Pathol. Clin. doi: 10.1016/j.path.2019.08.002 contributor: fullname: Al Rasheed – volume: 17 start-page: 154 issue: 1 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0055 article-title: Therapeutic advances in anaplastic thyroid cancer: a current perspective publication-title: Mol. Cancer doi: 10.1186/s12943-018-0903-0 contributor: fullname: Saini – volume: 27 start-page: 5502 issue: 20 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0225 article-title: Phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-21-0761 contributor: fullname: Zheng – volume: 159 start-page: 676 issue: 3 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0130 article-title: Integrated genomic characterization of papillary thyroid carcinoma publication-title: Cell doi: 10.1016/j.cell.2014.09.050 contributor: fullname: Cancer Genome Atlas Research Network – volume: 36 start-page: 7 issue: 1 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0330 article-title: Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2017.73.6785 contributor: fullname: Subbiah – volume: 30 start-page: 1856 issue: 12 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0010 article-title: Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up† publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdz400 contributor: fullname: Filetti – volume: 29 start-page: 1869 issue: 8 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0365 article-title: Selective RET kinase inhibition for patients with RET-altered cancers publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1093/annonc/mdy137 contributor: fullname: Subbiah – volume: 21 start-page: 5640 issue: 24 year: 2015 ident: 10.1016/j.bbcan.2023.188928_bb0300 article-title: Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib-response publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2298 contributor: fullname: Rothenberg – volume: 30 start-page: 13 issue: 1 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0465 article-title: The year in medical thyroidology review: current challenges and future directions publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2019.0792 contributor: fullname: Busaidy – volume: 187 start-page: R53 issue: 3 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0455 article-title: MANAGEMENT OF ENDOCRINE DISEASE: medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-22-0312 contributor: fullname: Saltiki – volume: 13 start-page: 909333 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0270 article-title: Vascular endothelial growth factor receptor inhibitors in Chinese patients with advanced radioactive iodine-refractory differentiated thyroid cancer: a network meta-analysis and cost-effectiveness analysis publication-title: Front. Endocrinol. doi: 10.3389/fendo.2022.909333 contributor: fullname: Zhu – volume: 23 start-page: 1 issue: 8 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0360 article-title: Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model publication-title: Health Technol. Assess. (Winchester, England) doi: 10.3310/hta23080 contributor: fullname: Tappenden – volume: 106 start-page: e3027 issue: 8 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0260 article-title: Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/clinem/dgab196 contributor: fullname: Lin – volume: 12 start-page: 245 issue: 2 year: 2005 ident: 10.1016/j.bbcan.2023.188928_bb0120 article-title: BRAF mutation in thyroid cancer publication-title: Endocr. Relat. Cancer doi: 10.1677/erc.1.0978 contributor: fullname: Xing – volume: 20 issue: 16 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0485 article-title: The immune landscape of thyroid cancer in the context of immune checkpoint inhibition publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20163934 contributor: fullname: Varricchi – volume: 19 start-page: 196 issue: 1 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0495 article-title: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer publication-title: BMC Cancer doi: 10.1186/s12885-019-5380-3 contributor: fullname: Mehnert – volume: 383 start-page: 825 issue: 9 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0275 article-title: Efficacy of selpercatinib in RET-altered thyroid cancers publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2005651 contributor: fullname: Wirth – volume: 79 start-page: 180 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0020 article-title: Molecular targets of tyrosine kinase inhibitors in thyroid cancer publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2020.11.013 contributor: fullname: Fallahi – volume: 17 start-page: 389 issue: 7 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0480 article-title: Endocrine toxicities of immune checkpoint inhibitors publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-021-00484-3 contributor: fullname: Wright – volume: 113 start-page: 7750 issue: 28 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0525 article-title: Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1605841113 contributor: fullname: Liu – volume: 13 start-page: 1055412 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0335 article-title: Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.1055412 contributor: fullname: Weng – volume: 33 start-page: 674 issue: 7 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0375 article-title: ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2022.04.009 contributor: fullname: Filetti – volume: 14 start-page: 3047 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0230 article-title: Management of progressive radioiodine-refractory thyroid carcinoma: current perspective publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S340967 contributor: fullname: Nervo – volume: 17 start-page: 36 issue: 1 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0070 article-title: Advances in studies of tyrosine kinase inhibitors and their acquired resistance publication-title: Mol. Cancer doi: 10.1186/s12943-018-0801-5 contributor: fullname: Jiao – volume: 7 start-page: 569 issue: 10 year: 2011 ident: 10.1016/j.bbcan.2023.188928_bb0085 article-title: Molecular genetics and diagnosis of thyroid cancer publication-title: Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2011.142 contributor: fullname: Nikiforov – volume: 16 start-page: 6009 issue: 24 year: 2010 ident: 10.1016/j.bbcan.2023.188928_bb0100 article-title: IQGAP1 plays an important role in the invasiveness of thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-10-1627 contributor: fullname: Liu – volume: 30 start-page: 134 issue: 2 year: 2012 ident: 10.1016/j.bbcan.2023.188928_bb0310 article-title: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2011.35.5040 contributor: fullname: Wells – volume: 31 start-page: 3639 issue: 29 year: 2013 ident: 10.1016/j.bbcan.2023.188928_bb0315 article-title: Cabozantinib in progressive medullary thyroid cancer publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2012.48.4659 contributor: fullname: Elisei – volume: 13 issue: 19 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0180 article-title: DNA methylation age drift is associated with poor outcomes and de-differentiation in papillary and follicular thyroid carcinomas publication-title: Cancers doi: 10.3390/cancers13194827 contributor: fullname: Liu – volume: 384 start-page: 319 issue: 9940 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0235 article-title: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(14)60421-9 contributor: fullname: Brose – volume: 38 start-page: 2773 issue: 24 year: 2020 ident: 10.1016/j.bbcan.2023.188928_bb0355 article-title: Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.19.02790 contributor: fullname: Kreissl – volume: 186 start-page: 631 issue: 6 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0305 article-title: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-21-1259 contributor: fullname: Waguespack – volume: 119 start-page: 1223 issue: 10 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0500 article-title: Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer publication-title: Br. J. Cancer doi: 10.1038/s41416-018-0296-2 contributor: fullname: Gunda – volume: 157 start-page: 153 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0430 article-title: intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: final results of the randomised, multicenter, open-label phase II trial PAZOTHYR publication-title: Eur. J. Cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2021.07.029 contributor: fullname: de la Fouchardière – volume: 15 start-page: 717 issue: 7 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0390 article-title: A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer publication-title: Future Oncol. (London, England) doi: 10.2217/fon-2018-0557 contributor: fullname: Takahashi – volume: 173 start-page: 260 issue: 1 year: 2023 ident: 10.1016/j.bbcan.2023.188928_bb0450 article-title: Medullary thyroid cancer with RET V804M mutation: more indolent than expected? publication-title: Surgery doi: 10.1016/j.surg.2022.05.005 contributor: fullname: Frisco – volume: 32 start-page: 1184 issue: 10 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0285 article-title: Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial publication-title: Thyroid Off. J. Am. Thyroid Assoc. contributor: fullname: Busaidy – volume: 93 start-page: 3106 issue: 8 year: 2008 ident: 10.1016/j.bbcan.2023.188928_bb0095 article-title: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2008-0273 contributor: fullname: Liu – volume: 367 start-page: 375 issue: 6461 year: 1994 ident: 10.1016/j.bbcan.2023.188928_bb0155 article-title: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma publication-title: Nature doi: 10.1038/367375a0 contributor: fullname: Hofstra – volume: 28 start-page: 4173 issue: 19 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0245 article-title: FDA approval summary: cabozantinib for differentiated thyroid cancer publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-22-0873 contributor: fullname: Duke – volume: 65 start-page: 125 year: 2014 ident: 10.1016/j.bbcan.2023.188928_bb0165 article-title: Thyroid cancer publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-061512-105739 contributor: fullname: Carling – volume: 22 start-page: 1126 issue: 8 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0250 article-title: Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00332-6 contributor: fullname: Brose – volume: 96 start-page: 1297 issue: 4 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0190 article-title: Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches publication-title: Physiol. Rev. doi: 10.1152/physrev.00041.2015 contributor: fullname: Beermann – volume: 21 start-page: 1028 issue: 5 year: 2015 ident: 10.1016/j.bbcan.2023.188928_bb0440 article-title: Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2915 contributor: fullname: Rothenberg – volume: 17 start-page: 1272 issue: 9 year: 2016 ident: 10.1016/j.bbcan.2023.188928_bb0280 article-title: Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30166-8 contributor: fullname: Brose – volume: 6 start-page: 68 issue: 1 year: 2018 ident: 10.1016/j.bbcan.2023.188928_bb0510 article-title: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0378-y contributor: fullname: Iyer – volume: 17 start-page: 225 issue: 4 year: 2021 ident: 10.1016/j.bbcan.2023.188928_bb0065 article-title: Multikinase inhibitors in thyroid cancer: timing of targeted therapy publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-020-00465-y contributor: fullname: Gild – volume: 29 start-page: 311 issue: 3 year: 2019 ident: 10.1016/j.bbcan.2023.188928_bb0030 article-title: Poorly differentiated carcinoma of the thyroid gland: current status and future prospects publication-title: Thyroid Off. J. Am. Thyroid Assoc. doi: 10.1089/thy.2018.0509 contributor: fullname: Ibrahimpasic – volume: 13 start-page: 943916 year: 2022 ident: 10.1016/j.bbcan.2023.188928_bb0520 article-title: Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: a case report and literature review publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.943916 contributor: fullname: Li |
| SSID | ssj0015336 |
| Score | 2.5074732 |
| SecondaryResourceType | review_article |
| Snippet | Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 188928 |
| SubjectTerms | Immune checkpoint inhibitors Multi-tyrosine kinase inhibitors Thyroid cancer |
| Title | Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities |
| URI | https://dx.doi.org/10.1016/j.bbcan.2023.188928 https://www.ncbi.nlm.nih.gov/pubmed/37257629 https://search.proquest.com/docview/2821639910 |
| Volume | 1878 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEB2lqQpcEAQKgRIZiWOd2N61d80tihoFokQoNMK3le1dS-ZgR2lyyIXfzozXroREe-jFX9LK65n1zBvN7BuALxhziLwwzOWGDjHTburljGhcC5ZrnhlGG4VX62ix5d-TMOnBrNsLQ2WVre23Nr2x1u2TSSvNya4sJz8pqcf9OEEQTaQ0yRmcozvivA_n02_Lxfo-mYCIxqYsPU5Jz6QjH2rKvLIMP2FMTcTHvpQxdWX_v4N6CIA2jmj-Cl62CNKZ2km-hp6pBnBhe0qeBvB81rVwG8CzVZs5fwObVdcH10HHVd45aaUdWwZu8MJyCzhlhZenfV1qJ6flsP_q_KACLjSHzYB6R3D9WDU0rG9hO7-5nS3ctp-Cm3OPH1yNoYGI0iASIspRc0FA5OronzMjUsmZZ7jRfqpTyQr8rbWUkRGRl6MH8woZG3YJ_aquzHtwpM6Z9MKC61BzLjIcnsrA1yLOtAyjbAjXnRDVztJmqK6e7LdqZK5I5srKfAhRJ2j1j_YVGvbHB37u1KJQtpTsSCtTH-8UhpI-oS_fG8I7q6_7mTBBYVYQf3jqaz_CC7qzZbtX0D_sj-YTgpNDNoKz8R9_1C5BOi83v5Z_AWDf46s |
| link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB6xRSxcEBQWyjNIe9zQJHZihxuqQOXRCvGQcrOS2JGyh7Qq7aH_npk4qYS0y4FLZCWy4nzjzHyjGc8A_EafQ-SFYS43dImZdlMvZ1TGtWC55plhdFB4NI6Gb_w-CZM1GLRnYSitstH9VqfX2rq502_Q7E_Lsv9CQT3uxwmSaCpKk_yAdR4KP-jA-vXdw3C8CiYgo7EhS49T0DNpiw_VaV5Zhp9wSU3EL30pY-rK_m8D9T8CWhui2x3Ybhikc20XuQtrpurChu0puezC5qBt4daFn6Mmcr4Hz6O2D66Dhqt8d9JKOzYN3ODA1hZwygqHy9mk1E5O22F25TxRAheqw3rCZEp0fVHVZVj34e325nUwdJt-Cm7OPT53NboGIkqDSIgoR8kFARVXR_ucGZFKzjzDjfZTnUpW4G-tpYyMiLwcLZhXyNiwX9CpJpU5BEfqnEkvLLgONeciw-mpDHwt4kzLMMp68KcFUU1t2QzV5pP9VTXmijBXFvMeRC3Q6pP0FSr2rydetGJRiC0FO9LKTBbvCl1Jn9iX7_XgwMprtRImyM0K4qPvvvYcNoevo0f1eDd-OIYtemJTeE-gM58tzCkSlXl21mzED7p-4_g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+basis+and+targeted+therapy+in+thyroid+cancer%3A+Progress+and+opportunities&rft.jtitle=Biochimica+et+biophysica+acta.+Reviews+on+cancer&rft.au=Zhang%2C+Lizhuo&rft.au=Feng%2C+Qingqing&rft.au=Wang%2C+Jiafeng&rft.au=Tan%2C+Zhuo&rft.date=2023-07-01&rft.eissn=1879-2561&rft.volume=1878&rft.issue=4&rft.spage=188928&rft_id=info:doi/10.1016%2Fj.bbcan.2023.188928&rft_id=info%3Apmid%2F37257629&rft.externalDocID=37257629 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-419X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-419X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-419X&client=summon |